Publications by authors named "T Dervieux"
Background: Infliximab (IFX) exposure is established as a predictive factor of pharmacokinetic (PK) origin in inflammatory bowel disease (IBD), and expert consensus is to achieve adequate exposure during induction to achieve and sustain remission.
Methods: We retrospectively evaluated the performance of a Bayesian PK tool in IBD patients starting IFX. Trough IFX serum levels collected immediately before the third (at week 6) and fourth (at week 14) infusions were evaluated from 307 IBD patients (median age=17 years, 50 % females, 83 % with Crohn's disease).
Background: Patients with Crohn's disease (CD) who lose response to biologics experience reduced quality of life (QoL) and costly hospitalizations. Precision-guided dosing (PGD) provides a comprehensive pharmacokinetic (PK) profile that allows for biologic dosing to be personalized. We analyzed the cost-effectiveness of infliximab (IFX) PGD relative to two other dose intensification strategies (DIS).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to identify poor prognostic factors related to pharmacokinetics that affect immune responses and disease control in inflammatory bowel disease (IBD) patients treated with infliximab or adalimumab.
- It found that certain baseline clearance rates and genetic variants (HLA DQA1*05) significantly increase the likelihood of forming antidrug antibodies, which negatively impact remission rates.
- Proactive therapeutic drug monitoring was shown to effectively mitigate these negative effects, especially when higher drug levels are maintained during treatment.
Crohn's disease (CD) is a chronic disorder of the digestive tract characterized by an uncontrolled immune-mediated inflammatory response in genetically predisposed individuals exposed to environmental risk factors. Although diet has been identified as one of the major environmental risk factors, the role of nutrients in the clinical management of CD patients has not yet been fully investigated. In this prospective observational study, fifty-four patients diagnosed with active Crohn's disease and undergoing anti-TNF-α biological therapy were enrolled and subjected to nutrient intake analysis through a daily food diary.
View Article and Find Full Text PDF